Patrick Neven

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge, Masakazu Toi, Patrick Neven et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Association analysis identifies 65 new breast cancer risk loci

Kyriaki Michailidou, Sara Lindström, Joe Dennis et al. · Nature · 2017 · 1.6K citations · Full text

Medicine, Bioinformatics, Oncology +12

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

Nasim Mavaddat, Kyriaki Michailidou, Joe Dennis et al. · The American Journal of Human Genetics · 2018 · 1.2K citations · Full text

Life Sciences, Biostatistics, Genetics +17

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Journal of Clinical Oncology · 2018 · 1.1K citations

Medicine, Oncology, Pharmacology +14

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacology +17